Don't expect too much too soon. Even Roy said not to expect much from the next report. It really won't be the following quarter that will tell all that much either. Those numbers will be deceiving due to the fact all the initial stocking orders will begin to show up. With those numbers (or preceding them) you should expect to see a pop in the share price. (that should off set the hangover from the 1st quarter Q)
Towards the end of the 2nd quarter, you should begin to find out about restocking numbers along with any additional sales outlets. There may be some exclusive contracts for large chains that agree to carry this product in the beginning.
Debt will mount since revenue always trails costs during expansion phases.
A good indicator of how things are going will be what kind of marketing campaign supports the product launch. Marketing campaigns are expensive, but if the company isn't willing to put a good one together the product will not sell itself. It won't have any recognition yet.
An example of bad marketing with a good product would be Cobroxin. It was voted best new product at marketing conferences but could not crack the pain medicine market. I know it's a good product because I have used it myself. Reviews from others have also been great, BUT poor marketing along with trying to break into an established market, has pretty much wiped out the company.
Stock went from .15 to almost $1 during the launch, but now trades
at less than .10.
Hopefully Roy does a better job with phaseIII
Also, there will ALWAYS be day traders, flippers and shorters affecting the price. They happen at every price point!
Market Data 
Markets 
AI
